Psychosis Management in Lewy Body Dementia: A Comprehensive Clinical Approach.
Karun BadwalShangwe A KiliakiSagar B DuganiSandeep R PagaliPublished in: Journal of geriatric psychiatry and neurology (2021)
Lewy body dementia (LBD) is asynucleinopathy that results in clinical manifestation of motor and neuropsychiatric symptoms. The disease burden associated with psychosis in LBD patients is significantly higher compared to other types of dementia or even to LBD without psychosis. Effective care management processes should include consideration of de-prescribing any offending agents including anticholinergics and dopaminergic agents, followed by nonpharmacological and low risk pharmacological approach. If addition of pharmacological agents is required, consideration should be given to acetylcholinesterase inhibitors, pimavanserin and atypical antipsychotics such as quetiapine or clozapine. Side effects of these medications should be considered prior to selection and initiation of a medication regimen. Goals of care and functional assessment are a crucial part of the optimized care plan, given overall guarded prognosis, in the context of numerous complications observed in this population. Palliative care consultation could facilitate symptom control and timely enrollment into hospice if consistent with patient's goals.
Keyphrases
- palliative care
- advanced cancer
- mild cognitive impairment
- healthcare
- end stage renal disease
- cognitive impairment
- quality improvement
- chronic kidney disease
- ejection fraction
- risk factors
- case report
- emergency department
- peritoneal dialysis
- prognostic factors
- global health
- depressive symptoms
- adverse drug
- patient reported outcomes
- patient reported
- sleep quality
- clinical evaluation